ethyl-isoxazol-5-ylmethyl-amine | 952195-14-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: ethyl-isoxazol-5-ylmethyl-amine
• 英文别名: N-(1,2-oxazol-5-ylmethyl)ethanamine
• CAS: 952195-14-1
• 化学式: C₆H₁₀N₂O
• mdl: MFCD14619071
• 分子量: 126.158
• InChiKey: SHRDKLOMTAZNGJ-UHFFFAOYSA-N

物化性质

• 沸点：
  199.7±15.0 °C(Predicted)
• 密度：
  1.020±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-溴甲基异恶唑 、 乙胺 以 四氢呋喃 为溶剂， 生成 ethyl-isoxazol-5-ylmethyl-amine
  参考文献：
  名称：

  NOVEL SULFONAMIDE COMPOUNDS

  摘要：

  本发明涉及新型磺酰胺化合物及其作为促进睡眠荷尔蒙受体拮抗剂的用途。

  公开号：

  US20090275588A1

文献信息

• Triazole compounds and methods of making and using the same
  申请人：Bhattacharjee Ashoke

  公开号：US20100016956A1

  公开（公告）日：2010-01-21

  The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. The compounds have the following structure: wherein T is the macrocyclic part.

  本发明提供了三唑大环化合物，作为治疗剂非常有用。更具体地说，这些化合物可用作抗感染、抗增殖、抗炎和促动力剂。化合物具有以下结构：其中T是大环部分。
• N-glycinsulfonamide derivatives and uses as orexin receptor antagonists
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：US08003654B2

  公开（公告）日：2011-08-23

  The invention relates to novel sulfonamide compounds of the formula (I) and their use as orexin receptor antagonists.

  该发明涉及一种新型磺酰胺化合物（I）及其作为促进睡眠荷尔蒙受体拮抗剂的用途。
• Triazole Compounds and Methods of Making and Using the Same
  申请人：Bhattacharjee Ashoke

  公开号：US20130065845A1

  公开（公告）日：2013-03-14

  The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.

  本发明提供了三唑大环化合物，其作为治疗剂具有用途。更具体地说，这些化合物可作为抗感染、抗增殖、抗炎和促动力剂使用。
• METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND
  申请人：Nishino Taito

  公开号：US20100266556A1

  公开（公告）日：2010-10-21

  An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various hematopoietic disorders is provided. A method for expanding hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises culturing hematopoietic stem cells and/or hematopoietic progenitor cells ex vivo in the presence of a compound represented by the formula (I) (wherein X, Y, X, Ar 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.
• Triazole Compounds And Methods Of Making And Using The Same
  申请人：Melinta Therapeutics, Inc.

  公开号：US20180094016A1

  公开（公告）日：2018-04-05

  The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.